Kochi M, Ushio Y (2002) Chemo-radiotherapy for malignant brain tumors. Gan To Kagaku Ryoho 29(5):669–676Kochi, M,Y. Ushio.Chemo-radiotherapy for malignant brain tumors.Gan To Kagaku Ryono. 2002Kochi M and Ushio Y: Chemo‑radiotherapy for malignant brain tumors. Cancer & chemotherapy 29...
[18].Mathis SE,et al. Chemo-predictive assay for targeting cancer stem-like cells in patients affected by brain tumors. PLoS One. 2014 Aug 21;9(8):e105710. [19].Howard CM,et al. Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer. Transl Oncol. 202...
[18]Mathis SE,et al. Chemo-predictive assay for targeting cancer stem-like cells in patients affected by brain tumors. PLoS One. 2014 Aug 21;9(8):e105710. [19]Howard CM,et al. Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer. Transl Oncol. 2020 ...
[16].Mathis SE,et al. Chemo-predictive assay for targeting cancer stem-like cells in patients affected by brain tumors. PLoS One. 2014 Aug 21;9(8):e105710. [17].Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF. Molecular mecha...
Novel chemosensitivity assay for targeting cancer stem-like cells in brain tumors Cancer stem-like cells (CSLCs) in primary brain tumors can resist certain chemotherapies, thereby causing relapse of the disease. Thus, development of a test that identifies the most effective chemotherapy management off...
Scientists at the University of Rochester in New York examined the neural impact of three chemotherapeutic drugs: cisplatin, often used to treat breast, lung, and colon cancer; carmustine, used to treat brain tumors; and cytarabine, a treatment for leukemia and some lymphomas. The drugs caused ...
In general, glioblastoma patients who are diagnosed with what is called MGMT methylated tumors tend to respond better to chemotherapy with TMZ. But this study found that MGMT methylation levels rise and fall based on the circadian time of the tumor. As a result, doctors should control for the...
The first clinical trial to demonstrate the feasibility of a convection-enhanced delivery (CED) system that acts as "chemosurgery" in the brainstem could revolutionize treatment for one of the deadliest central nervous system tumors of childhood, according to researchers. ...
tumors, the improved survival with morning chemotherapy was more pronounced. Patients with this tumor type tend to respond better to temozolomide in general. For the 56 patients with MGMT methylated tumors, average overall survival was about 25½ months for those taking the drug in the morning ...
Interferon As Adjuvant Therapy For Malignant Melanoma Ewing's Sarcoma Symptoms and Treatment Focused Ultrasound: Latest Tool for Fighting Cancer Hyperthermia: New Hope For The Old Method Of Cancer Treatment Risks factors for oesophageal cancer Pediatric Brain Tumors: Radiation Therapy for Treatment...